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In this study, we will show you the results of a survey that has
been conducted on patients who have taken the treatment course
as a part of the trails, carried by dermatologists and inventors,
aiming to give an initial assessment. Data was collected from 100
randomly selected patients through an online form of a
questionnaire covering the evaluation of the treatment results,
patients physical and psychological impacts, and their general
information about the condition.
Patent WO20200588091A showed to be responsive among
all age groups where 96% had repigmentation. On the other
hand, 12% develop recurrence in the treated areas after
abandoning the treatment. The treatment shows promising
results on all types of vitiligo except segmental and acral
vitiligo which showed to be more challenging in achieving
full repigmentation.
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There are increasing data that showed that low antioxidant
activities and oxidative stress contribute with vitiligo
pathogenesis. The results of decrease catalase activity elevated
hydrogen peroxide and peroxynitrite concentration, lipid
peroxidation reaction, and inhibition of tyrosinase activity1,2 which
is vital for melanogenesis, and all are events that fall under the
treatment’s hypothesis.
Primary objectives:
1. To gather information and statistics from patients
2. To assess the treatment response on a different population
Hypothesis: The treatment hypothesis suggests that treatment of
immunosuppressants or immunomodulators alone might
temporarily reduce the autoimmune action but might not stop the
accumulation of Chemokines and other oxidants-antioxidants.
And other imbalances occurring in melanocytes create a
possibility of recurrence. The antioxidant treatment alone is not
exactly immunosuppressant/modulators or anti-inflammatory or
stimulates the generation of melanocytes and should be combined
with immuno-modulatory and phototherapy that will cause the
radiation trauma triggering melanocyte production but at the
same time protective from excess ROS damage that might occur
(preserving the tolerance of vitiligo causing genes).
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Image 1: Radiation Control 
compared with VT and Radiation. 
Image 2: Results on Vitiligo Vulgaris. 
Image 3: Elbow joint. 
Image 4: Hand wrist and palm. Image 5: Acral vitiligo. 
Image 6: Complete 
repigmentation case of acral 
vitiligo. 
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